

Cipla invests £100 million in UK subsidiary

11 July 2014 | News | By BioSpectrum Bureau

Cipla invests £100 million in UK subsidiary



Said The Right Honourable George Osborne, Chancellor of the Exchequer, Her Majesty's Government of the United Kingdom, "I am happy to be able to announce that Indian pharmaceutical company Cipla will invest up to £100 million in the UK. The investment will fund the launch of a range of drugs in the areas of respiratory, oncology and anti-retroviral medicines as well as R&D, clinical trials and further expansion internationally and in the UK."

On the occasion of the 66th anniversary of the British National Health Service (NHS), Cipla believes that by providing high quality affordable medicines for patients, it can contribute cost effective solutions for the NHS.

"We are very pleased to be making this investment in the UK. We were impressed with the pro-active support and engagement that the UK Government and its various ministries showed in attracting Cipla to choose the UK as a key hub in

our global footprint," said Mr Rajesh Garg, global chief financial officer and member of the board of Cipla.